Akebia therapeutics inc AKBA.US 總覽分析

美股醫療保健
(AKBA 無簡報檔)

AKBA 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等,已經有部位可以持續持有,若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

AKBA 近期報酬表現

-4.71%

Akebia therapeutics inc

4.57%

同產業平均

3.26%

S&P500

與 AKBA 同產業的標的表現

  • TEM Tempus ai inc
    價值 -趨勢 3 分波段 3 分籌碼 3 分股利 1 分
    查看更多

AKBA 公司資訊

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company's portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

AKBA 股價